- Drugs List
- Therapeutic Indications
- Precautions and Warnings
- Pregnancy and Lactation
- Side Effects
Eye drops containing tafluprost.
Treatment of elevated intraocular pressure in ocular hypertension
Treatment of elevated intraocular pressure in open-angle glaucoma
Reduction of elevated intraocular pressure in ocular hypertension or in open angle glaucoma; as monotherapy in patients intolerant or insufficiently responsive to first line therapy; as adjunctive to beta-blockers.
Instil 1 drop into the affected eye(s) once daily in the evening.
Children under 18 years
Precautions and Warnings
Females of childbearing potential
Predisposition to iritis
Predisposition to uveitis
Risk factors for cystoid macular oedema
Anterior chamber lens
Narrow angle glaucoma
Pseudophakia with open angle glaucoma
Pseudophakia with torn posterior lens capsule
Advise patient blurred vision may affect ability to drive/operate machinery
Advise patient hair growth may occur on areas of skin repeatedly exposed
In combined therapy, administer eye products at least five minutes apart
To reduce systemic absorption compress lacrimal sac during administration
Advise patient that some eye changes may be permanent
Female: Ensure adequate contraception during treatment
Advise patient not to exceed stated dose
Advise patient to avoid touching the eye/other surfaces with container tip
Before initiating treatment inform patient of possibility of eyelash growth
Before initiating treatment inform patient of risk of eyelid skin darkening
Before starting treatment inform patient of risk of increased iris pigment
Pregnancy and Lactation
Use tafluprost with caution during pregnancy.
The manufacturer recommends this medication is not used during pregnancy unless the potential benefit to the mother outweighs the potential risk to the foetus. Animals studies have shown reproductive toxicity. At the time of writing there is limited human data available. Risks are unknown.
Tafluprost must not be used in women of childbearing potential unless adequate contraceptive measures are used.
Tafluprost is contraindicated during breastfeeding.
The manufacturer notes tafluprost is not to be used during breastfeeding. Animal studies show excretion of tafluprost and/or its metabolites in breast milk after topical administration. At the time of writing it is unknown if tafluprost and/or its metabolites are excreted in human milk. A decision should be made to discontinue breastfeeding if tafluprost is of greater benefit to the mother.
Abnormal sensation in eye
Aggravation of existing asthma
Anterior chamber flare
Cells in anterior chamber of eye
Cystoid macular oedema
Hypertrichosis of eyelid
Increased iris pigmentation
Reduced visual acuity
Sensation of foreign body in eye
Superficial punctate keratitis
It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management.
The following number will direct the caller to the relevant local centre (0844) 892 0111
Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet ( www.toxbase.org ) or if this is unavailable at the backup site ( www.toxbasebackup.org ).
Last Full Review Date: October 2019
Summary of Product Characteristics: Saflutan 15micrograms/ml eye drops, solution in single-dose container. Santen UK Limited. November 2017.
Summary of Product Characteristics: Saflutan 15micrograms/ml eye drops, solution. Santen UK Limited. February 2019.
Already a member? Log in
Medscape UK | Univadis prescription drug monographs & interactions are based on FDB Multilex Content
FDB Disclaimer : FDB Multilex is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.